CHF患者应用不同剂量阿托伐他汀的相关性分析  

Correlation analysis of different doses of atorvastatin in patients with CHF

作　　者：李慧[1] 赵建荣[1] Li Hui;Zhao Jian-rong(Luwan Branch of Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University,Shanghai 200020,China)

机构地区：[1]上海交通大学医学院附属瑞金医院卢湾分院

出　　处：《中西医结合心血管病电子杂志》2019年第28期12-13,共2页Cardiovascular Disease Electronic Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的分析CHF患者应用不同剂量阿托伐他汀类药物与血浆高敏C反应蛋白水平的相关性。方法入选自2016年5月~2018年5月本院收治的慢性心力衰竭患者130例,以随机数字表法原则分组,分对照组(65例,在慢性心衰标准治疗的基础上+10 mg阿托伐他汀)、研究组(65例,在对照组的基础上,调整阿托伐他汀为20 mg),比较两组治疗前后NT-proBNP、hs-CRP,及sST-2。结果治疗12周后研究组NTproBNP、hs-CRP水平显著较对照组低,差异有统计学意义(P<0.05)。加用不同剂量他汀药物治疗的患者ST-2也有明显差异,且与NT-proBNP呈正相关性,差异有统计学意义(P<0.05)。结论他汀类药物可有效降低慢性心力衰竭患者NT-proBNP、hs-CRP水平,同时可联合NT-proBNP与ST-2增加对患者预后的预测能力,应当引起临床重视与关注。Objective To analyze the correlation between dose of statin and plasma hypersensitive c-reactive protein levels in CHF patients.Methods A total of 130 CHF patients admitted to our hospital between May 2016 to May 2018,grouped according to the random number table method principle,divided into 2 groups.The control group(65 cases,with standard treatment of CHF+atorvastatin 10mg)and study group(65 cases,with standard theraphy+atorvastatin 20mg),compared the two groups with the biomarks NT-proBNP,hs CRP and sST-2.Results After 12 weeks of treatment,NT-proBNP and hs-CRP levels in the study group were significantly lower than those in the control group,P<0.05.There were also significant differences in ST-2 among patients treated with different doses of statins(P<0.05).Conclusion Statins can effectively reduce the levels of NT-proBNP and hs-CRP in patients with chronic heart failure.sST-2 and NT-proBNP can increase the ability to predict the prognosis of patients,which should be paid attention to clinically.

关 键 词：慢性心力衰竭 阿托伐他汀 血浆高敏C反应蛋白 N末端B型利钠肽前体 可溶性ST-2 

分 类 号：R541[医药卫生—心血管疾病]